Evaluation of the Clinical Effects of Ombitasvir/Paritaprevir/ Ritonavir Regimen in the Treatment of Chronic HCV Patients in CKD Versus ESRD Patients in Assiut University Hospital | ||||
The Medical Journal of Cairo University | ||||
Article 97, Volume 87, March, March 2019, Page 803-808 PDF (433.57 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/mjcu.2019.52539 | ||||
View on SCiNiTO | ||||
Authors | ||||
SHALA Kh. EL-SHERIF, M.D.; ESSAM M. ABD EL-AZIZ, M.D.; MONA ABD EL-LATIF ALI, M.Sc. | ||||
The Departments of Internal Medecine & Endocrinology and Npherology, Faculty of Medicine, Assiut University, Egypt | ||||
Abstract | ||||
Abstract Background: Assesing curability of Ombitasvir/Parit-aprevir/Ritonavir regimen in chronic HCV infected patients in those with ESRD and CKD. Aim of Work: To asses, curability of Ombitasvir/Paritap-revir/Ritonavir in chronic HCV infected patients in those with ESRD vs CKD, and assess duration of sustained viral therapy in Assiut Hospital University. Patients and Methods: It is a prospective study which included 40 patients at Hemodialysis unit and Internal Medicine department in Assiut University Hospitals though one year. Then Patient will be divided into 2 group: Group I: 20 ESRD Patients on regular heamodialysis >6 months with chronic HCV infection. Group II: 20 CKD Patients with chronic HCV infection did not start dialysis. Results: (SVR) was assessed at 12 and 24 weeks post-therapy. All patients in each group achieved SVR at 12 weeks but at 24 week. 85% of patients with ESRD achieved SVR while all those with CKD achieved SVR. Conclusion: We found that the curability of Ombitasvir /Paritaprevir/Ritonavir plus Ribavirin has SVR12 about 100% and SVR24 100% in CKD patients, 85% in ESRD patients. With less incidence of anemia with that regimen as only 10% patients need blood transfusion. With high tolerability and less side effects with no occurrence of discontinuation of treatment. | ||||
Keywords | ||||
Treatment of HCV in renal impairment | ||||
Statistics Article View: 122 PDF Download: 185 |
||||